N-(tert-butoxycarbonyl)piperidin-2-one

We are N-(tert-butoxycarbonyl)piperidin-2-one CAS:85908-96-9 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

CAS No: 85908-96-9
Product Name: N-(tert-butoxycarbonyl)piperidin-2-one
Other Name:
N-(tert-butoxycarbonyl)piperidin-2-one
N-Boc-2-piperidone
tert-butyl 2-oxopiperidine-1-carboxylate
2-Methyl-2-propanyl 2-oxo-1-piperidinecarboxylate
1-boc-1-azacyclohexan-2-one
 
Density: 1.1±0.1 g/cm3
Boiling Point: 319.7±11.0 °C at 760 mmHg
Melting Point: 34-37°C
Molecular Formula: C10H17NO3
Molecular Weight: 199.247
Flash Point: 147.1±19.3 °C
Exact Mass: 199.120850
PSA: 46.61000
LogP: 0.60
Vapour Pressure: 0.0±0.7 mmHg at 25°C
Index of Refraction: 1.481
Storage condition: Refrigerator
 
Specification
Appearance: White powder
Assay: ≥99.0%
Water: ≤0.50%
 
Application
Be used as pharmaceutical intermediate, apixaban intermediate.
Intermediate in the preparation of various biological inhibitors.
 
Package: 25kg/drum, can also be designed according to customer requirements.
Storage: Store in cool place. Keep container tightly closed in a dry and well-ventilated place.

N-(tert-butoxycarbonyl)piperidin-2-one


Related News: According to the business type, it can be divided into non-CMO business of APIs and intermediates and CMO business of APIs and intermediates.2-Formylbenzeneboronic acid ICIG will also supply materials needed for the manufacture of other treatments in earlier stages of development, including neo-GAA, currently in preclinical development as a potential next-generation Pompe disease therapy.Pentafluorophenol Fate Therapeutics, Inc. recently announced new in vivo preclinical data for FT819, its first off-the-shelf, iPSC-derived chimeric antigen receptor (CAR) T-cell product candidate, at the 61st American Society of Hematology (ASH) Meeting and Exposition in Orlando, FL.Ethyl 2-chloroacetoacetate Especially tumor drugs with selective targeting characteristics. At present, about 80% of small drug (high-efficiency drug) APIs worldwide are patented drugs.Especially tumor drugs with selective targeting characteristics. At present, about 80% of small drug (high-efficiency drug) APIs worldwide are patented drugs.

Related Products
Product Name
2-Chloro-4-methoxy-3-nitropyridine View Details
1-Ethoxycarbonyl-5-methyl-(3R)-3-tert-butyl-dimethylsilyloxypentanedioate View Details
Copper Nitrate View Details
2-Fluoroethanamine hydrochloride Cas:460-08-2 manufacturer 2,7-Dibromo-9-(4-bromophenyl)-9H-carbazole manufacturer 1-Hydroxyethylethoxypiperazine manufacturer Ethyl dichlorophosphate manufacturer CAS:18406-41-2 Bis-(trimethoxysilyl)ethane manufacturer